A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

KAHTNU Surgical Receives $2M Funding: To Expand Worldwide Sales

Partners with U.K. Ortho Consulting Group for Global Sales Expansion

What To Know

  • KAHTNU Surgical also announced a partnership with United Kingdom-based Ortho Consulting Group Ltd (OCG) to establish and support KAHTNU Surgical sales channels outside the United States.
  • The investment will help KAHTNU Surgical aggressively expand worldwide sales and marketing efforts as well as broaden and accelerate product development for spine and orthopedic surgeons.

July 15, 2020

KAHTNU Surgical, a U.S. medical technology company based in Alaska, announced today it had completed a $2.15 million Series A round of financing led by Kinetic Medical Co., Ltd. The investment will help KAHTNU Surgical aggressively expand worldwide sales and marketing efforts as well as broaden and accelerate product development for spine and orthopedic surgeons.

KAHTNU Surgical provides a range of products for spine and orthopedic surgery. Most notably KAHTNU Surgical provides the KASILOF Cervical Plate, CHENA-C PEEK Spacer and TALKEETNA Pedicle Screw systems for spine surgery. “This funding will accelerate the company’s ability to establish quality sales channels in the U.S. and aggressively expand our product development capabilities,” says Craig Wilcox, President and CEO. “KAHTNU Surgical is committed to product development that harnesses existing and emerging technologies to improve outcomes for spine and orthopedic surgeons and their patients,” notes Wilcox.

KAHTNU Surgical also announced a partnership with United Kingdom-based Ortho Consulting Group Ltd (OCG) to establish and support KAHTNU Surgical sales channels outside the United States. “Ortho Consulting Group’s team of industry experts brings a broad array of capabilities to KAHTNU, driving our European, and Outside U.S. KOL selection process, marketing, sales, distribution, training, logistics and operations. We are delighted to partner with OCG,” says Wilcox.

Andrew Dubowski, Ortho Consulting Group Commercial Director, adds: “We are thrilled to partner with KAHTNU Surgical. The commitment they show to provide high quality/cost-effective products in the spine industry makes this an exciting addition to our client portfolio. We are looking forward to helping KAHTNU Surgical grow globally.” More information on Ortho Consulting Group is at Orthocg.com.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

With this new investment partnership, E Tech Group expects to accelerate organic growth and acquisition to become a top system integrator in North America.
The investment will allow ROM InWest to further distribute its fall detection product globally.
Nawal Ouzren, Sensorion’s Chief Executive Officer, said: “We are thrilled to announce another successful capital raise, securing an additional EUR 15 million to accommodate interest expressed by certain existing investors. This builds on the earlier EUR 50 million financing announced in February 2024, adding up to a total of EUR 100 million raised in less than 9 months. With this new financing, we are well-positioned to accelerate our gene therapy programs, including the progression of SENS-501 through its Phase 1/2 clinical study, Audiogene, and the advancement of our second program, GJB2-GT, towards Clinical Trial Applications submission in H1 2025. The capital increase enables the Company to finance its activities until the end of 2025. We remain deeply thankful for the ongoing support of our shareholders and partners as we strive to make a meaningful difference in the lives of those affected by hearing loss disorders.”
Strategic Investor, Osang Healthcare will partner with Kryptos Biotechnologies for the manufacturing and distribution of the product along with financing.
Proceeds from the financing will advance Obsidian’s lead engineered tumor-infiltrating lymphocyte (TIL) program, OBX-115, in its ongoing trials for patients with melanoma and non-small cell lung cancer (NSCLC). Obsidian Therapeutics is focused on enrolling patients and reaching key clinical and regulatory milestones, as well as manufacturing scale-up ahead of pivotal trial readiness.

By using this website you agree to accept Medical Device News Magazine Privacy Policy